Every 8-K that Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (FBIOP) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow FBIOP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full FBIOP filings page.
Fortress Biotech, Inc. (FBIO) repaid in full the remaining $15.0 million in principal under its Oaktree Agreement on September 30, 2026. It also paid approximately $435,000 in accrued interest, a $150,000 prepayment fee and other closing costs.
Following repayment, all indebtedness under the agreement was satisfied and paid in full, all liens and other security interests securing it were released and terminated, and the agreement automatically terminated pursuant to its terms.
Fortress Biotech, Inc. reported second-quarter 2026 net revenue of $18.7 million, a 14% increase over the same quarter in 2025. Product revenue reached $17.8 million, and total net revenue for the first six months of 2026 was $34.8 million, up from $29.6 million a year earlier.
Despite higher revenue, the quarter showed a net loss attributable to common stockholders of $2.5 million, compared with net income of $13.4 million in the prior-year quarter. For the first half of 2026, net income attributable to common stockholders was $105.9 million, driven largely by a $158.9 million gain from the sale of a priority review voucher and other investment-related items.
The balance sheet strengthened notably: cash and cash equivalents were $196.6 million as of June 30, 2026, up from $79.4 million at year-end 2025. Total assets rose to $316.7 million, while long-term notes payable declined to $34.6 million. Total stockholders’ equity increased to $206.1 million, from $62.2 million at December 31, 2025.
Fortress Biotech reported the results of its 2026 annual meeting of stockholders held virtually on June 17. Stockholders voted on electing seven directors to serve until the 2027 meeting and on ratifying KPMG LLP as independent registered public accounting firm for the year ending December 31, 2026.
Each director nominee, including Lindsay A. Rosenwald, Jimmie Harvey Jr., Malcolm Hoenlein, Dov Klein, J. Jay Lobell, Kevin L. Lorenz, and Michael S. Weiss, received more votes "For" than "Against." The proposal to ratify KPMG LLP also received substantially more votes "For" than "Against," based on the reported vote totals.
Fortress Biotech reported a sharp turnaround in the first quarter of 2026, driven by monetizing a Rare Pediatric Disease Priority Review Voucher for $205 million. This generated a gain on sale of $158.9 million and lifted net income attributable to common stockholders to $108.4 million, or $3.44 basic and $2.82 diluted EPS, compared with a loss a year earlier.
Net revenue rose to $16.0 million, up from $13.1 million, while operating loss narrowed as selling, general and administrative and research and development costs declined. Cash and cash equivalents increased to $255.8 million, and total stockholders’ equity grew to $202.4 million. Management highlighted FDA approval of ZYCUBO for Menkes disease, expected future royalties from ZYCUBO and UNLOXCYT, and debt reduction, including lowering Oaktree principal to $15.0 million, as key steps supporting its diversified portfolio strategy.
Fortress Biotech reported that its majority-owned subsidiary Cyprium Therapeutics has closed the sale of its Rare Pediatric Disease Priority Review Voucher for $205 million in gross proceeds under a previously disclosed asset purchase agreement. In connection with the transaction, Cyprium redeemed all outstanding shares of its 9.375% Perpetual Preferred Stock.
Fortress, which owns 80.4% of Cyprium’s outstanding common stock on an as-converted basis, expects to receive at least $100.0 million from Cyprium through potential future dividends and intercompany agreements, including intercompany debt, interest and accrued expenses. Cyprium must pay 20% of the PRV sale proceeds to an institute of the National Institutes of Health and also remains eligible to receive tiered royalties on net sales of ZYCUBO and up to approximately $128 million in aggregate sales milestones from Sentynl Therapeutics.
Fortress Biotech’s majority-owned subsidiary Cyprium Therapeutics agreed to sell its FDA Rare Pediatric Disease Priority Review Voucher for $205 million in cash, payable at closing. The voucher was granted after ZYCUBO was approved to treat Menkes disease in pediatric patients.
Fortress owns 80.4% of Cyprium’s common stock and expects to receive at least $100 million over time from Cyprium through dividends and intercompany arrangements, subject to closing, taxes, required payments to a National Institutes of Health institute, Cyprium’s preferred stock redemption and other obligations. Fortress also amended its Oaktree credit agreement to ease several financial covenants after the PRV sale and to apply $10 million of proceeds, plus interest and a yield protection premium, to mandatory loan prepayment.
Fortress Biotech, Inc. furnished a press release that provides a corporate update and announces its financial results for the quarter ended June 30, 2025.
The press release is included as Exhibit 99.1 and is furnished, not filed, meaning it is not subject to certain liability provisions and is not automatically incorporated into other securities law filings.